# A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

> **NCT05803421** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 2749 (actual)

## Conditions studied

- Type 2 Diabetes
- Obesity
- Overweight or Obesity
- Overweight
- Cardiovascular Diseases
- Chronic Kidney Disease

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT05803421
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-03
- **Primary completion:** 2026-03-16
- **Final completion:** 2026-03-16
- **Target enrollment:** 2749 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05803421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05803421, "A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05803421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*